Reception
The reception area is near the entrance. We will be happy to help you here.
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University Hospital and German Cancer Aid (Deutsche Krebshilfe). Our aim is to couple the promising concepts in cancer research with patient care, from diagnostics to therapies, after-care and prevention models. Located between the Head Hospital (Kopfklinik) and the Children’s Hospital (Kinderklinik), the NCT building provides the ideal space for the achievement of this target.
Oncological research and patient care are closely intertwined at the NCT Heidelberg. Intensive networking is further supported by the building itself. The spacious structure with open stairway encourages meetings on all levels.
The reception area is near the entrance. We will be happy to help you here.
Eating, an essential basic human need, is often severely affected by the illness, the therapy and the psychological strains caused by cancer. It is important to recognize and treat nutritional problems as early as possible. A team of nutritional scientists is available to you at the NCT to answer any questions you might have about nutrition.
Sabrina Grzimek created this 2.4 m high bronze figure in the NCT foyer. It depicts the founder of German Cancer Aid (Deutsche Krebshilfe), Dr. Mildred Scheel.
A cancer diagnosis raises many concerns about the consequences of the disease way beyond the medical questions. Our social services team will be happy to help you with uncertainties regarding rehabilitation, the disabilities act, social benefits, employment and financial support.
The central contact point is coordination office B („Leitstelle B”). This is where you will be able to discuss your specific concerns.
The central contact point is coordination office A („Leitstelle A“). This is where you will be able to discuss your specific concerns.
Opening hours 8 am – 4 pm
The cafeteria is located opposite the entrance area on level 01. It offers a range of warm and cold drinks, sandwiches, cakes and snacks.
The central contact point is coordination office D („Leitstelle D”). This is where you will be able to discuss your specific concerns.
A tumor board consists of a group of experts who discuss the condition and finding of the individual patient. Tumor board meetings are an integral part of the NCT concept. They concentrate the professional competence of an oncologic center of excellence: The expertise and experience of physicians meet the knowledge and skills of scientists, resulting in an optimized treatment proposal. The involvement of physicians of different fields of expertise ensures the high quality of the following treatment.
Treatment of cancer means a strong physical and psychological burden. Exercise or structured physical training can help to reduce or even prevent side effects both during and after cancer treatment. Furthermore, tumor patients themselves can positively influence their subjective well-being through exercise and sports. For this reason the NCT offers all its patients comprehensive sports and exercise counseling and support.
As Head of the Department of Medical Oncology, Prof. Dirk Jäger is responsible for the clinical infrastructure and patient care at the NCT. Through additional intensive research work, the Medical Oncology Department is aiming to bring the latest basic research results into clinical application. The main focus here is on investigating innovative therapy approaches and creating new concepts to delay tumor progression.
The Department of Translational Oncology coordinates all major aspects of NCT´s further development and translational oncology at DKFZ. As part of the translational cancer research process, the department is deeply involved in the clinical activities of NCT and contributes to trial development, with a special focus on molecular diagnosis and therapy.
Prof. Hermann Brenner, head of the DKFZ Division of Clinical Epidemiology and Aging Research, serves as temporary head of the Division Preventive Oncology since November 2014. Under his leadership, a research agenda focusing on novel avenues of cancer screening and early detection is currently being built up. A second research focus on risk adapted prevention will be developed for the future.